Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762616 | 0.91 | BDKRB1 (0.49) | BDKRB1 | |
| SCHEMBL6766725 | 0.85 | BDKRB1 (0.63) | BDKRB1 | |
| SCHEMBL6762272 | 0.85 | BDKRB1 (0.47) | BDKRB1PPARG | |
| SCHEMBL6763224 | 0.82 | BDKRB1 (0.53) | BDKRB1PPARG | |
| SCHEMBL6760016 | 0.78 | BDKRB1 (0.49) | BDKRB1PPARG | |
| SCHEMBL6762608 | 0.77 | BDKRB1 (0.67) | BDKRB1 | |
| SCHEMBL6764048 | 0.77 | BDKRB1 (0.65) | BDKRB1 | |
| SCHEMBL6759974 | 0.76 | BDKRB1 (0.54) | BDKRB1PPARG | |
| SCHEMBL6763217 | 0.75 | BDKRB1 (0.73) | BDKRB1PPARG | |
| SCHEMBL6766954 | 0.74 | BDKRB1 (0.51) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885PPARG 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.